by Deborah Erickson
Calling on the Norwalk, CT headquarters of Purdue Frederick Co./Purdue Pharma LP reminds one just how very private this mid-sized...
One big drug is dramatically expanding the ambitions of family-owned Purdue. Now the mid-sized firm is aggressively pursuing in-licensing opportunities and building its own research capacity. Its size and private status allow it to craft flexible terms for a broad range of drugs, without worrying about Wall St. But can this inward focused company adapt to the more public requirement of its aggressive growth plans?
by Deborah Erickson
Calling on the Norwalk, CT headquarters of Purdue Frederick Co./Purdue Pharma LP reminds one just how very private this mid-sized...
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.